Ph.D. William Benton Jones - 04 Jun 2025 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Reporting relationship: SVP, Pharmaceutical Development
Issuer ticker: CRVS
Reported as of: 04 Jun 2025
Net transaction value: +$67,750
SEC form: 4
Accepted by SEC: 06 Jun 2025, 16:26:07 UTC
Prior SEC filing: 23 Dec 2024
Next SEC filing: 08 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Leiv Lea, as Attorney-in-Fact for William Benton Jones, Ph.D.

Key filing fact

Ph.D. William Benton Jones filed Form 4 for Corvus Pharmaceuticals, Inc. (CRVS) on 06 Jun 2025.

Key facts

This page summarizes Ph.D. William Benton Jones's Form 4 filing for Corvus Pharmaceuticals, Inc. (CRVS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jun 2025, 16:26.

Change

Previous filing in this sequence was filed on 23 Dec 2024.
Current net transaction value: +$67,750.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001664506 Primary reporting owner

Jones William Benton

Relationship: SVP, Pharmaceutical Development
Address: C/O CORVUS PHARMACEUTICALS, INC., 901 GATEWAY BOULEVARD, THIRD FLOOR, SOUTH SAN FRANCISCO
Signature: /s/ Leiv Lea, as Attorney-in-Fact for William Benton Jones, Ph.D.
Signature date: 06 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRVS transaction

Common Stock

Options Exercise

Transaction value: $67,750
Shares: +19,357
Change %: +13%
Price: $3.50
Shares after: 173,130
Date: 04 Jun 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRVS transaction Derivative

Warrant (Right to Buy)

Options Exercise

Transaction value
Shares: -19,357
Change %: -100%
Price
Shares after: 0
Date: 04 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,357
Exercise price: $3.50
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Issued at no additional consideration to the Reporting Person in connection with their subscription for shares of the Issuer's Common Stock at a price of $1.7312 per share.

SEC remarks

SVP, Pharmaceutical Development